OrthoPediatrics (KIDS) Reports Q3 Earnings: What Key Metrics Have to Say

Core Insights - OrthoPediatrics reported $61.25 million in revenue for Q3 2025, a 12.2% year-over-year increase, but fell short of the Zacks Consensus Estimate of $62.59 million by 2.14% [1] - The company posted an EPS of -$0.24, compared to -$0.18 a year ago, with a surprise of +7.69% against the consensus estimate of -$0.26 [1] Financial Performance - The stock has returned -7.4% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change [3] - OrthoPediatrics holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Product Sales Breakdown - Trauma and deformity product sales reached $44.14 million, slightly below the average estimate of $44.65 million, reflecting a year-over-year increase of 17.3% [4] - Sports medicine/other product sales were $0.85 million, significantly lower than the average estimate of $1.13 million, marking a year-over-year decline of 34.7% [4] - Scoliosis product sales totaled $16.26 million, slightly below the average estimate of $16.8 million, with a year-over-year change of +4% [4]